Illustration of Tetrabenazine packaging

Notice: Product images are for illustration purposes only and may differ from the medication you receive. Packaging and appearance may vary depending on the country of origin, and generic medications may be supplied by different manufacturers. The medication, strength, and active ingredients will match your prescription. At the Canadian Pharmacy Store we prioritize your health and safety by working with licensed pharmacy partners to provide safe, high-quality medications.

GenericActive ingredient: TetrabenazineNeurology medications

Tetrabenazine

Other Brands:Nitoman, Xenazine

Tetrabenazine (Generic)

Tetrabenazine

Sourced from Canada Source: Canada
Prescription Required
Select product strength & quantity:

Tetrabenazine (Generic)

Tetrabenazine

Sourced from Mauritius Source: Mauritius
Prescription Required
Select product strength & quantity:
Select Strength & Quantity

Choose the strength, form, and package size that match your prescription.

Send Your Prescription

Upload your prescription online, request a transfer, or have your doctor fax us.

Pharmacist Review & Delivery

Reviewed by a licensed pharmacist and shipped to your U.S. address with tracking. Shipping details.

Description

Tetrabenazine (tetrabenazine) is a vesicular monoamine transporter 2 inhibitor listed in our Neurology medications directory and prescribed for conditions within neurology medications (1.1) (2.1). Administered via the oral route, Tetrabenazine is available for delivery to U.S. residents through Canadian Pharmacy Store with a valid prescription. Review the clinical fact table, dosage directions, cautions, drug interactions, side effects, and official regulatory sources below.

Tetrabenazine is a medication containing the active pharmaceutical ingredient tetrabenazine, classified pharmacologically as a vesicular monoamine transporter 2 inhibitor (2.1). It is clinically indicated for the management of conditions within neurology medications as part of a comprehensive treatment plan supervised by a licensed healthcare provider (2.1).

Within the Neurology medications section of our catalogue, patients and prescribers frequently review Tetrabenazine alongside related therapies such as Nitoman (Tetrabenazine), Xenazine (Tetrabenazine), Almotriptan, and Amantadine Hydrochloride.

Official Indications and Usage

Tetrabenazine tablets are indicated for the treatment of chorea associated with Huntington’s disease. (1.1)

Clinical Pharmacology

Mechanism by which tetrabenazine exerts its anti-chorea effects is unknown but is believed to be related to its effect as a reversible depletor of monoamines (such as dopamine, serotonin, norepinephrine, and histamine) from nerve terminals. Tetrabenazine reversibly inhibits the human vesicular monoamine transporter type 2 (VMAT2) (Ki ≈ 100 nM), resulting in decreased uptake of monoamines into synaptic vesicles and depletion of monoamine stores. Human VMAT2 is also inhibited by dihydrotetrabenazine (htbz), a mixture of α-htbz and β-htbz. α- and β-htbz, major circulating metabolites in humans, exhibit high in vitro binding affinity to bovine VMAT2. Tetrabenazine exhibits weak in vitro binding affinity at the dopamine D2 receptor (K i = 2100 nM). (1.1)

Ordering Tetrabenazine from Canada for U.S. Delivery

U.S. patients can order Tetrabenazine (Tetrabenazine) in U.S. dollars with a valid prescription from a U.S.-licensed clinician. Your card is only charged after your prescription passes pharmacist safety checks and is ready to ship.

Step 1

Send Your Prescription

Step 2

Pharmacist Safety Check

  • Multi-point dosing and interaction review completed in under 1 business day.
  • Mandatory licensed pharmacist consultation via phone, voicemail, or text before dispatch.
  • Verified under our Pharmacy Safety Standards.
Step 3

$14.99 USD Tracked Parcel

  • Packed in discreet protective packaging for a flat $14.99 USD per order ($29.99 if combined with cold-chain).
  • Tracked via Canada Post and USPS: 3 to 7 business days from Canada (7 to 14 days from international partners).
  • Review full shipping and delivery details.
Step 4

U.S. Street Delivery & Payment

  • Delivered to any physical U.S. street address with signature upon delivery (no P.O. Boxes).
  • You see and approve the country of origin upfront before your card is charged.
  • Report any delayed or damaged parcel within 48 hours for prompt resolution.

Fact Table

Clinical Specification Details
Brand / Product Name Tetrabenazine
Chemical / Generic Name Tetrabenazine
Pharmacological Class Vesicular Monoamine Transporter 2 Inhibitor
Therapeutic Category Neurology medications
Same-Ingredient Catalogue Entries Nitoman (Tetrabenazine), Xenazine (Tetrabenazine)
Elimination Half-Life ~17.5 hours (1.1)
Legal Status Rx-Only (Prescription Required)
Regulatory Reference Authorities U.S. FDA (DailyMed), Health Canada (DPD)
Routes of Administration Oral
Dosage Forms & Strengths Tetrabenazine tablets, USP are available in the following strengths and packages: The 12.5 mg Tetrabenazine tablets, USP are light yellow to yellow, round
Primary Indications Conditions Within Neurology Medications
Pregnancy & Breastfeeding Consult Doctor / Prescriber before use
FDA UNII Identifier Z9O08YRN8O
NLM RxNorm Concept ID (RxCUI) 199592, 805464
FDA Application License ANDA213316
Official DailyMed SetID 5042f30c-c922-4835-bf6d-40905f2dc76c
Catalogue Index Links Letter T Index · All Medications · All Categories

Directions

Dosage and Administration Overview

  • Individualization of dose with careful weekly titration is required. The 1 st week’s starting dose is 12.5 mg daily; 2nd week, 25 mg (12.5 mg twice daily); then slowly titrate at weekly intervals by 12.5 mg to a tolerated dose that reduces chorea.
  • Doses of 37.5 mg and up to 50 mg per day should be administered in three divided doses per day with a maximum recommended single dose not to exceed 25 mg.
  • Patients requiring doses above 50 mg per day should be genotyped for the drug metabolizing enzyme CYP2D6 to determine if the patient is a poor metabolizer (PM) or an extensive metabolizer (EM).
  • Maximum daily dose in PMs: 50 mg with a maximum single dose of 25 mg.
  • If serious adverse reactions occur, titration should be stopped and the dose should be reduced. If the adverse reaction(s) do not resolve, consider withdrawal of tetrabenazine. (1.1)

Presentations and Strengths

Tetrabenazine tablets, USP are available in the following strengths and packages: The 12.5 mg Tetrabenazine tablets, USP are light yellow to yellow, round shaped, flat, beveled edge tablets, debossed with “T” 12.5 on one side and plain on other side. Tablets: 12.5 mg non-scored and 25 mg with functional score. (1.1)

Administration Guidance

Take Tetrabenazine orally at the same time(s) each day as directed on your prescription label (1.1). Check with your pharmacist whether your specific formulation should be taken with a meal or on an empty stomach, and swallow extended-release or film-coated tablets whole without crushing, chewing, or splitting unless the tablet is scored and your prescriber has instructed you to do so.

Missed Dose Guidance

If you miss a scheduled dose of Tetrabenazine, follow the missed-dose instructions in the official patient leaflet or ask your pharmacist. Do not double the next dose to make up for a missed dose (2.1).

Ingredients

Active Pharmaceutical Ingredient

The active ingredient in Tetrabenazine is tetrabenazine (2.1). Other catalogue entries containing tetrabenazine include Nitoman (Tetrabenazine) and Xenazine (Tetrabenazine).

Inactive Ingredients (Excipients)

According to the U.S. FDA product labeling, formulation excipients include lactose monohydrate, pregelatinized starch, ferric oxide yellow, talc and magnesium stearate (1.1). Inactive ingredients can vary slightly between different manufacturers and international or generic presentations; review the dispensed carton if you have known excipient sensitivities.

Cautions and important safety information

Boxed Warning

Warning: depression and suicidality Tetrabenazine can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Anyone considering the use of tetrabenazine tablets must balance the risks of depression and suicidality with the clinical need for control of chorea. Close observation of patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior should accompany therapy. Patients, their caregivers, and families should be informed of the risk of depression and suicidality and should be instructed to report behaviors of concern promptly to the treating physician. (1.1)

Contraindications

Tetrabenazine tablets are contraindicated in patients: Who are actively suicidal, or in patients with untreated or inadequately treated depression. With hepatic impairment. Taking monoamine oxidase inhibitors (MAOIs). Tetrabenazine tablets should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI. Taking reserpine. At least 20 days should elapse after stopping reserpine before starting tetrabenazine tablets. Taking deutetrabenazine or valbenazine (1.1):

  • Actively suicidal, or who have depression which is untreated or undertreated.
  • Hepatic impairment.
  • Taking monoamine oxidase inhibitors (MAOIs) or reserpine.

Key Clinical Precautions

Before starting or continuing Tetrabenazine, discuss your complete medical history with your healthcare provider. Key clinical cautions include (1.1):

  • Suicidal ideation and behavior monitoring: Patients, especially children, adolescents, and young adults starting or changing doses of centrally acting therapies, should be closely monitored for worsening mood, agitation, or emergence of suicidal thoughts.
  • Cardiovascular events: Depending on the medication class and underlying medical history, patients should be monitored for signs of cardiovascular events such as chest pain, shortness of breath, sudden weakness, or slurred speech.
  • Neuroleptic Malignant Syndrome (NMS): A rare, potentially fatal symptom complex characterized by hyperpyrexia (high fever), muscle rigidity, altered mental status, and autonomic instability.
  • Cardiac conduction and QT interval: Caution is advised in patients with known arrhythmias, bradycardia, electrolyte disturbances (hypokalemia or hypomagnesemia), or concomitant QT-prolonging medications.
  • Renal function and acute kidney injury: Changes in serum creatinine or estimated glomerular filtration rate (eGFR) can occur, particularly in patients with volume depletion, chronic kidney disease, or concomitant use of NSAIDs, ACE inhibitors, ARBs, or diuretics. Renal function should be assessed prior to initiation and periodically thereafter.
  • Hypotension and volume depletion: Intravascular volume contraction can cause symptomatic low blood pressure, orthostatic dizziness, or fainting, especially in older adults, patients with impaired renal function, or those taking diuretics. Ensure adequate hydration before and during therapy.

Pregnancy, Lactation, and Special Populations

Pregnancy: Based on animal data, may cause fetal harm. There are no adequate data on the developmental risk associated with the use of tetrabenazine tablets in pregnant women. Administration of tetrabenazine to rats throughout pregnancy and lactation resulted in an increase in stillbirths and postnatal offspring mortality. Administration of a major human metabolite of tetrabenazine to rats during pregnancy or during pregnancy and lactation produced adverse effects on the developing fetus and offspring (increased mortality, decreased growth, and neurobehavior- al and reproductive impairment). (1.1)

Interactions

Official Drug Interaction Overview

CYP2D6 Inhibitors In vitro studies indicate that α-htbz and β-htbz are substrates for CYP2D6. Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine, quinidine) markedly increase exposure to these metabolites. A reduction in tetrabenazine dose may be necessary when adding a strong CYP2D6 inhibitor (e.g., fluoxetine, paroxetine, quinidine) in patients maintained on a stable dose of tetrabenazine tablets. The daily dose of tetrabenazine tablets should not exceed 50 mg per day and the maximum single dose of tetrabenazine tablets should not exceed 25 mg in patients taking strong CYP2D6 inhibitors. (1.1)

Important Interaction Categories

Concomitant use of Tetrabenazine with certain prescription medications, over-the-counter drugs, or supplements can alter how the medication works or increase the risk of side effects. Important interaction categories to review with your prescriber and pharmacist include (2.1):

  • Monoamine oxidase inhibitors (MAOIs, such as phenelzine, tranylcypromine, selegiline, or linezolid): Concomitant use or use within 14 days of stopping an MAOI can cause severe drug interactions, including hypertensive crisis, serotonin syndrome, or enhanced hypoglycemic and central nervous system effects.
  • Alcohol: Excessive alcohol consumption can potentiate blood-sugar fluctuations, increase the risk of lactic acidosis or ketoacidosis in metabolic therapies, heighten gastrointestinal irritation, or increase drowsiness and orthostatic dizziness.

Side effects

Like all medications, Tetrabenazine can cause side effects, although not everyone experiences them. Commonly reported side effects in clinical trials and official labeling include (1.1):

  • Nausea (feeling sick): Often mild to moderate and most noticeable when starting therapy or increasing the dose; taking oral doses with food (when permitted by the label) may help.
  • Vomiting: Persistent vomiting that prevents fluid intake should be reported to your clinician to prevent dehydration.
  • Diarrhea (loose stools): Maintain adequate fluid and electrolyte intake; contact your prescriber if diarrhea is severe or persistent.
  • Headache: Commonly reported during initial treatment; often improves as your body adjusts to the medication.
  • Dizziness or lightheadedness: May occur especially when standing up quickly from a sitting or lying position (orthostatic changes); rise slowly and stay well hydrated.
  • Drowsiness or somnolence: Use caution with driving or tasks requiring alertness until you know how this medication affects you.

Clinical Trial and Postmarketing Adverse Reactions

The following serious adverse reactions are described below and elsewhere in the labeling (1.1):

  • Depression and Suicidality.
  • Neuroleptic Malignant Syndrome (NMS).
  • Akathisia, Restlessness, and Agitation.
  • Parkinsonism.
  • Sedation and Somnolence.
  • QTc Prolongation.
  • Hypotension and Orthostatic Hypotension.
  • Hyperprolactinemia.

When to Seek Immediate Medical Attention

Contact your physician or seek urgent medical care if you experience signs of a severe allergic reaction (hives, difficulty breathing, or swelling of the face, lips, tongue, or throat), severe dizziness or fainting, unexplained severe pain, or any sudden change in your clinical symptoms (2.1).

Storage and handling

Tablets, USP are available in the following strengths and packages: Tetrabenazine tablets, USP 12.5 mg are formulated as light yellow to yellow, round shaped, flat, beveled edge tablets, debossed with “T” 12.5 on one side and plain on other side. Bottles of 112: NDC 23155-938-63 Tetrabenazine tablets, USP 25 mg are formulated as light yellow to yellow, round shaped, flat, beveled edge tablets, debossed “T 25” on one side and functional scoreline on other side. Bottles of 112: NDC 23155-939-63 Store at 25º C (77º F); excursions permitted to 15° to 30ºC (59° to 86º F). (1.1)

Store Tetrabenazine in its original container at controlled room temperature away from excess heat, direct light, and moisture (such as bathroom cabinets), and keep out of reach of children and pets (1.1).

What is a generic drug?

A generic medication contains the exact same active pharmaceutical ingredient (tetrabenazine) as its brand-name counterpart and is formulated to deliver the same dosage strength, route of administration, safety profile, quality, and therapeutic performance (2.1). Regulatory authorities require generic manufacturers to demonstrate bioequivalence, meaning the generic medication releases its active ingredient into the bloodstream at virtually the same rate and to the same extent as the innovator brand.

While a generic tablet, capsule, or inhaler may differ in color, shape, scoring, or packaging due to trademark laws that govern brand appearance, its clinical mechanism and active ingredient match the reference medicine. Because generic manufacturers do not repeat the initial discovery and multi-phase clinical trial investments of the original brand, generic equivalents offer substantial cost savings for patients paying out of pocket.

Canadian Pharmacy Store delivers prescription and over-the-counter medications to U.S. residents. Browse our Neurology medications directory, explore all medications A-Z, review how ordering works and prescription requirements, or call 1-888-868-1920 for personal assistance matching your prescription.

Frequently Asked Questions About Tetrabenazine

What is Tetrabenazine and what active ingredient does it contain?

Tetrabenazine is a vesicular monoamine transporter 2 inhibitor containing the active pharmaceutical ingredient tetrabenazine. It is supplied for oral administration and requires a valid prescription where applicable.

How does Tetrabenazine work in the body?

Tetrabenazine (tetrabenazine) works through targeted pharmacological pathways in its class (vesicular monoamine transporter 2 inhibitor) to support the clinical management of conditions within neurology medications.

What conditions is Tetrabenazine prescribed to treat?

Tetrabenazine is primarily indicated for conditions within neurology medications. Your prescribing clinician determines the appropriate indication, strength, and treatment duration based on your individual diagnosis and medical history.

How should I take or use Tetrabenazine?

Follow the exact dosage, frequency, and administration instructions printed on your prescription label. Tetrabenazine is administered via the oral route. Take it consistently at the same time(s) as directed, and never adjust your dose or stop therapy without speaking with your prescriber.

What are the most common side effects of Tetrabenazine?

Commonly reported side effects of Tetrabenazine include feeling sick, vomiting, loose stools, headache, dizziness, and sleepiness. Most mild side effects improve as your body adjusts to treatment, but you should notify your doctor or pharmacist if symptoms persist or worsen.

What medications or substances can interact with Tetrabenazine?

Important interaction categories for Tetrabenazine include monoamine oxidase inhibitors and alcohol. Always share a complete list of your prescription drugs, over-the-counter medicines, vitamins, and herbal supplements with your pharmacist before starting treatment.

Can Tetrabenazine be used during pregnancy or breastfeeding?

If you are pregnant, planning to become pregnant, or breastfeeding, consult your prescribing physician before using Tetrabenazine to weigh the clinical benefits and potential risks.

Do I need a prescription to buy Tetrabenazine online from Canada?

Yes. A valid prescription written by a U.S.-licensed physician, nurse practitioner, or physician assistant is required to buy Tetrabenazine (Tetrabenazine) through our licensed Canadian pharmacy partners. Valid prescriptions go through multiple safety checks in less than 1 business day, followed by a mandatory request to speak with a licensed pharmacist for a consultation (watch your phone, voicemails, and text messages).

What is the brand-name version of Tetrabenazine (Tetrabenazine) at a Canada pharmacy?

Yes. Tetrabenazine is the bioequivalent generic formulation of brand-name Nitoman, Xenazine, containing the same active ingredient (Tetrabenazine) and strength options.

How is Tetrabenazine shipped to U.S. residents, and how much does shipping cost?

Tetrabenazine ships in discreet protective packaging at a flat rate of $14.99 USD per order via Canada Post and USPS with full tracking (if combined in the same order with a cold-chain item, total shipping is $29.99 USD in a larger container). Once your valid prescription passes safety checks (<1 business day) and you respond to the mandatory licensed pharmacist consultation request via phone, voicemail, or text message, delivery takes 3 to 7 business days from Manitoba, Canada (or 7 to 14 business days from licensed partner pharmacies in the UK, Singapore, and Mauritius). You see and choose the country of origin before you pay, and your Visa, Mastercard, or Discover card is only charged when your order is ready to ship.

How can I send or transfer my Tetrabenazine prescription, or ask about an unlisted strength?

You can upload a clear photo or PDF of your Tetrabenazine prescription online, request a prescription transfer or direct prescriber coordination from our team, or have your prescriber fax the prescription directly to (844) 666 – 6819. You may order up to a 90-day personal-use supply per shipment. If you do not see your exact prescribed strength or manufacturer listed, call 1-888-868-1920 and our staff will check availability across our licensed pharmacy partners.

References & Official Sources

Clinical, pharmacological, and safety facts for Tetrabenazine are compiled directly from official regulatory prescribing labels and primary biomedical databases:

  1. (1.1) Tetrabenazine. U.S. National Library of Medicine / U.S. Food and Drug Administration (DailyMed). Official U.S. FDA / DailyMed Structured Product Labeling (SPL). (Accessed 2026-10-29).
  2. (2.1) Health Canada Drug Product Database (DPD), Authorized Product Records. Health Canada / Government of Canada. Health Canada Drug Product Database & Official Product Monograph. (Accessed 2026-10-29).

Related Guides

Call 1-888-868-1920Help